The FDA has sent warning letters to 30+ telehealth companies, referred Hims & Hers to the DOJ, and declared it will use "all available enforcement tools" against compounded GLP-1 sellers. Here's what you need to know.
If you're currently using compounded semaglutide or considering it, the regulatory landscape has shifted dramatically in early 2026. What was a gray area in 2024 and early 2025 — when drug shortages gave compounding pharmacies a legal pathway to produce semaglutide — has narrowed into what legal experts describe as "a tightly policed corridor." Understanding what happened, what it means for your medication, and what options remain is important for anyone in this space.
GLP-1 medications were in shortage from 2022 through early 2025. When an FDA-approved drug is in shortage, compounding pharmacies can legally produce copies under Section 503A (patient-specific, from state-licensed pharmacies) and Section 503B (larger-scale outsourcing facilities). This was a legitimate, legal pathway designed to protect patient access.
The problem was scale. What started as patient-specific compounding for individual prescriptions quickly became mass production and mass marketing. Telehealth platforms and compounding pharmacies began advertising compounded semaglutide at a fraction of branded prices, often directly to consumers through digital advertising. Some added B vitamins or other ingredients to argue their products weren't "essentially copies" of FDA-approved drugs.
When the FDA declared the semaglutide shortage resolved in February 2025, the legal basis for most compounding evaporated. The agency gave 503A pharmacies 60 days and 503B outsourcing facilities 90 days to wind down production. Instead of winding down, prescriptions increased, according to data firm IQVIA.
The enforcement action accelerated rapidly in February 2026:
February 5, 2026: Hims & Hers launched a compounded oral semaglutide tablet, marketing it as containing the same active ingredient as Wegovy while noting it was not FDA-approved.
February 6, 2026: The FDA publicly announced its intent to take "decisive steps" to restrict GLP-1 APIs used in non-FDA-approved compounded products. The same day, the HHS General Counsel referred Hims & Hers to the Department of Justice for investigation.
February 7, 2026: Hims & Hers pulled the compounded semaglutide pill from its platform.
March 2026: The FDA sent warning letters to 30 telehealth companies for misleading advertising of compounded GLP-1 products. Letters stated that claims comparing compounded products to FDA-approved drugs, or implying equivalent safety and effectiveness, are false and misleading.
Ongoing: The FDA has sent thousands of advisory and warning letters since September 2025, and stated that failure to address violations may result in seizure and injunction without further notice.
The FDA's enforcement doesn't constitute a blanket ban on all compounding. The distinction matters:
Still legal (narrow pathway): Patient-specific compounding by a state-licensed pharmacy under Section 503A, where the patient has a documented medical necessity that cannot be met by an FDA-approved product — for example, a documented allergy to an inactive ingredient in Wegovy/Ozempic, or a need for a dosage form that doesn't exist commercially. This requires a valid, individual prescription based on a genuine clinical need.
No longer legal: Mass production of semaglutide copies by compounding pharmacies or outsourcing facilities when the drug is not in shortage. Marketing compounded products as alternatives to FDA-approved drugs. Advertising that compounded products have the same active ingredient or produce equivalent results. Selling compounded GLP-1 products directly to consumers without legitimate patient-specific medical necessity.
The FDA's crackdown isn't purely a pharmaceutical industry turf war. There are genuine safety issues that have emerged:
Dosing errors: The FDA has received multiple reports of adverse events — some requiring hospitalization — from dosing errors with compounded injectable semaglutide. Patients measured and self-administered incorrect doses, and in some cases healthcare professionals miscalculated doses. Multi-dose vials in non-standard concentrations create opportunities for error that don't exist with pre-filled pens.
Unapproved salt forms: Some compounding pharmacies have used semaglutide sodium or other salt forms rather than semaglutide base (which is the form in FDA-approved products). These alternative salts are considered unapproved new drugs — their safety and efficacy have not been established, and their bioavailability may differ from the approved form.
Cold chain failures: Injectable GLP-1 medications require refrigeration. Compounded products shipped directly to consumers may arrive warm or with inadequate cold packs, potentially degrading the product before the patient ever uses it.
Outright fraud: The FDA has identified products labeled with pharmacy names that either don't exist or didn't actually compound the product. Counterfeit compounded semaglutide and tirzepatide are a growing concern. At least one adverse event has been linked to a product from a pharmacy that didn't compound it.
The primary driver of compounded semaglutide demand has been cost. When Wegovy's list price was $1,349/month and insurance coverage was spotty, compounded versions at $200–$400/month were compelling despite the regulatory uncertainty.
That price gap is narrowing. In February 2026, Novo Nordisk announced it will reduce list prices for Wegovy and Ozempic to $675/month, effective January 1, 2027 — a 50% cut for Wegovy and 35% for Ozempic. The company's direct-to-consumer self-pay price for injectable Wegovy is already $349/month, with $199/month for new patients in their first two months. Wegovy tablets (launched January 2026) start at $149/month at the lowest dose through direct-to-consumer channels.
As brand-name prices continue to drop and insurance coverage expands (especially with the Medicare Part D changes taking effect), the cost advantage of compounded products shrinks. When you factor in the quality, safety, and legal risks of compounded products, the calculus increasingly favors FDA-approved options.
Wegovy injection (self-pay): $349/month ($199/month for new patients, first 2 months)
Wegovy tablets (self-pay): $149–$299/month depending on dose
Ozempic injection (self-pay): $349–$499/month depending on dose
List price (Jan 2027): $675/month across all semaglutide products
With commercial insurance: As low as $25/month with manufacturer copay cards
If you're currently using a compounded semaglutide product, don't panic — but do plan a transition.
Talk to your provider. If your prescriber is a legitimate, licensed physician or nurse practitioner, they can help you transition to an FDA-approved product. If your "provider" is a telehealth platform that only offers compounded medications, that's a sign to find a new provider.
Check your insurance. Coverage for Wegovy and Zepbound has expanded significantly. Many commercial insurance plans now cover these medications, especially for patients with BMI ≥ 30 or BMI ≥ 27 with comorbidities. Prior authorization may be required, but coverage is more likely than it was a year ago.
Explore self-pay options. At $349/month for injectable Wegovy or $149/month for Wegovy tablets at starting doses, FDA-approved semaglutide is approaching the price point where many compounded versions were selling. The quality, safety, and legal certainty of FDA-approved products make them worth the modest premium.
Don't abruptly stop. If you've been on compounded semaglutide and can't immediately access an FDA-approved alternative, work with your provider on a transition plan. Abrupt discontinuation can lead to appetite rebound and rapid weight regain.
These providers offer FDA-approved GLP-1 medications at competitive self-pay prices with proper medical oversight:
$350 CPA — FDA-approved GLP-1 programs
Prescribes authentic, FDA-approved semaglutide and tirzepatide with full medical oversight and monitoring.
Get Started →$350 CPA — physician-led weight loss
Board-certified providers prescribing FDA-approved medications. Structured titration protocols for safe dose escalation.
Learn More →$300 CPA — weight loss programs
Transparent pricing on FDA-approved GLP-1 medications with comprehensive medical evaluations.
Check Pricing →Affordable FDA-approved GLP-1 access
Competitive pricing on authentic medications with proper prescriber oversight.
Check Availability →